Other Resources
About Boston Scientific
Boston Scientific's history began in the late 1960s, when co-founder John Abele acquired an equity interest in Medi-tech, Inc., a research and development company focused on developing alternatives to traditional surgery. Medi-tech's first products, a family of steerable catheters, were introduced in 1969 and were used in some of the first less-invasive procedures. Versions of these steerable catheters are still used today. In 1979, John Abele and Pete Nicholas partnered to buy Medi-tech and together formed Boston Scientific Corporation. Driven by the needs of the medical community for innovative products, the Company grew from revenues of approximately $2 million in 1979 to more than $8.3 billion in 2007.
During 2007, we marked our third year of leadership in the U.S. market for drug-eluting stents (DES), maintaining between 53 percent and 56 percent market share for 10 consecutive quarters. We also became the global DES market leader during 2007. As we enter 2008, we are well positioned to sustain that leadership with key new products, an impressive body of clinical evidence to support approval of expanded indications for DES, the broadest range of stent size offerings in the industry and our experienced R&D, marketing and sales organizations.
This reference provides reimbursement information on TAXUS Drug-Eluting Stent procedures. 
